

Cagrilintide + Semaglutide Dosing Chart

The investigational fixed combination of the amylin analog cagrilintide with the GLP-1 agonist semaglutide, developed for greater weight loss. Commonly discussed doses: 2.4 mg–2.4 mg. The combination is dosed once weekly after titration, with each component at a fixed amount. Figures reflect published phase 3 dosing. This is investigational data, not a prescribing guide.

thelastpeptide.com · Medically reviewed by Charles Maddix, MSN, APRN, PMHNP-BC · Last reviewed 2026-08-02

FDA STATUS

Not FDA-approved. CagriSema (cagrilintide with semaglutide) is an investigational combination in clinical development and has not been approved.

10 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	2.4 mg
1 mL	10	24 u
2 mL	5	48 u
3 mL	3.33	72 u

"—" means the draw exceeds one syringe at that concentration. Interactive calculator for any combination: thelastpeptide.com/peptides/cagrilintide-plus-semaglutide

Cagrilintide + Semaglutide dose figures are commonly discussed reference information with no approved labeling unless stated above. The Last Peptide is an educational reference and sells nothing. Dosing figures shown here are commonly discussed reference information, not prescriptions or medical advice. Many peptides listed are not FDA-approved. Talk to a licensed clinician before using any peptide.